Video
Author(s):
Jacqueline S. Garcia, MD, instructor in medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the management of thrombocytopenia with navitoclax in patients with myelofibrosis.
Jacqueline S. Garcia, MD, instructor in medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the management of thrombocytopenia with navitoclax in patients with myelofibrosis.
Navitoclax can induce thrombocytopenia, which can be a problem for patients with advanced myelofibrosis who don't have normal platelet levels. However, in a phase II trial, investigators were able to manage thrombocytopenia with a slow ramp-up of navitoclax and an individualized dose based on the patient’s platelet level, says Garcia. Alternatively, the dose of navitoclax could have been reduced.
With this approach, no evidence of clinically significant bleeding was observed. Patients who remained on the combination by weeks 6 to 8 experienced thrombocytopenia, but this was expected and consistent with the use of ruxolitinib (Jakafi), concludes Garcia.
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL
Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment
Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer
Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC
2 Commerce Drive
Cranbury, NJ 08512